1	Advances in the molecular neurobiology of posttraumatic stress disorder from global contexts: A
2	systematic review of longitudinal studies
3	
4	Jacqueline S Womersley ^{1,2*} , Morne du Plessis ^{1,2} , M Claire Greene ³ , Leigh L van den Heuwel ^{1,2} , Eugene
5	Kinyanda ^{4,5} , Soraya Seedat ^{1,2}
6	¹ Department of Psychiatry, Stellenbosch University, Cape Town, South Africa
7	² South African Medical Research Council / Stellenbosch University Genomics of Brain Disorders
8	Extramural Unit, Stellenbosch University, Cape Town, South Africa
9	³ Program on Forced Migration and Health, Heilbrunn Department of Population and Family Health,
10	Columbia University Mailman School of Public Health, New York, NY, USA.
11	⁴ MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda
12	⁵ Department of Psychiatry, College of Health Sciences, Makerere University, Kampala, Uganda.
13	
14	* Corresponding author: Jacqueline Womersley (jsw1@sun.ac.za)
15	
16	
17	
18	
	This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI. 10.1017/gmh.2023.53 This is an Open Access article, distributed under the terms of the Creative Commons
	Attribution-NonCommercial-NoDerivatives licence

(http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

19 Abstract

Trauma exposure is prevalent globally and is a defining event for the development of posttraumatic 20 21 stress disorder (PTSD), characterised by intrusive thoughts, avoidance behaviours, hypervigilance 22 and negative alterations in cognition and mood. Exposure to trauma elicits a range of physiological 23 responses which can interact with environmental factors to confer relative risk or resilience for 24 PTSD. This systematic review summarises the findings of longitudinal studies examining biological 25 correlates predictive of PTSD symptomology. Databases (Pubmed, Scopus and Web of Science) were 26 systematically searched using relevant keywords for studies published between 1 January 2021 and 27 31 December 2022. English language studies were included if they were original research 28 manuscripts or meta-analyses of cohort investigations that assessed longitudinal relationships 29 between one or more molecular-level measures and either PTSD status or symptoms. Eighteen of 30 the 1042 records identified were included. Studies primarily included military veterans/personnel, 31 individuals admitted to hospitals after acute traumatic injury, and women exposed to interpersonal 32 violence or rape. Genomic, inflammation and endocrine measures were the most commonly 33 assessed molecular markers and highlighted processes related to inflammation, stress responding, 34 and learning and memory. Quality assessments were done using the Systematic Appraisal of Quality 35 in Observational Research and the majority of studies were rated as being of high quality, with the 36 remainder of moderate quality. Studies were predominantly conducted in upper-income countries. 37 Those performed in low- and middle-income countries were not broadly representative in terms of 38 demographic, trauma type and geographic profiles, with three out of the four studies conducted 39 assessing only female participants, rape exposure, and South Africa, respectively. They also did not 40 generate multimodal data or use machine learning or multilevel modelling, potentially reflecting greater resource limitations in LMICs. Research examining molecular contributions to PTSD do not 41 42 adequately reflect the global burden of the disorder.

44 Impact statement

Though most people experience at least one traumatic event in their lifetime, only a subset go on to 45 46 develop PTSD. Biological mechanisms play an important role in determining risk and resilience. 47 Advances in molecular technologies and data analytic procedures now provide unprecedented 48 insights into the molecular aetiology underlying PTSD. Ideally, identification of biological correlates 49 of PTSD should be used to stratify trauma-exposed individuals according to risk, target preventative 50 measures and interventions accordingly, identify biological targets for therapeutic modulation and 51 track treatment response. This systematic review provides a synthesis of the evidence-base globally, 52 highlights key mechanisms and approaches used in molecular research, and compares and contrasts 53 the nature and form of the literature base in upper- and low- and middle-income countries. Studies 54 drawing on different biological markers, including genotypic, epigenetic, transcriptomic, 55 endocrinological and serum level data, consistently point to the role of the stress response, 56 inflammation, and learning and memory in PTSD symptomology. Contingent risk granted by these 57 mechanisms depend on environmental and demographic factors. Our search results indicate a 58 mismatch between the global trauma burden and the research conducted, with studies primarily 59 conducted in upper income countries. Detailed investigations of the molecular mechanisms 60 underlying PTSD in diverse populations and contexts is required if the promise offered by biological 61 insights is to be globally relevant, actionable and equitable.

62

63 Keywords

64 Posttraumatic stress disorder, genomics, global health, trauma, neurobiology

65

67

68 Introduction

69 Trauma exposure is prevalent worldwide with approximately 70% of people reporting exposure to at 70 least one traumatic event in their lifetime (Benjet et al. 2016). Based on analysis of 26 population 71 surveys, around 5.6% of trauma-exposed individuals will go on to develop posttraumatic stress 72 disorder (PTSD), which is characterised by symptoms of hyperarousal, reexperiencing, avoidance and 73 negative alterations to cognition and mood (American Psychiatric Association 2013; Koenen et al. 74 2017). Though PTSD contributes to poor mental health globally, low- or middle-income countries 75 (LMICs) are disproportionately affected. Not only is the total population of LMICs substantially 76 higher than that in upper-income countries (UICs), but these regions also suffer from a dual burden 77 of potent stressors and limited mental health care resources (Purgato and Olff 2015). For example, 78 the age-standardised prevalence of PTSD in conflict settings is approximately 15.3% and this burden 79 is primarily in LMICs (Charlson et al. 2019). Hoppen et al estimated that in 2019, more than 99% of 80 adults who had experienced war in the preceding 30 years resided in LMICs, which by extrapolation 81 accounts for approximately 3.1 million PTSD-associated disability-adjusted life years in these 82 countries (Hoppen et al. 2021). In addition, factors, such as higher socioeconomic status, living 83 standards, community infrastructure and use of mental health services, which protect against the 84 developmental of posttraumatic stress (PTS) following disasters and pandemics may be less 85 prevalent in LMICs (Newnham et al. 2022).

86

87 Neurobiology of traumatic stress outcomes

88 Biological mechanisms grant contingent risk or resilience and contribute to the considerable

- 89 interindividual variability in posttraumatic stress (PTS) symptom presentation, severity, trajectory,
- 90 and treatment response (Ressler et al. 2022). Translational neuroscience provides evidence for

91	genomics, neural circuitry and neurotransmission aberrations and dysregulated immune system
92	processes as causes or correlates of PTSD. PTSD is unique among disorders in requiring a
93	precipitating traumatic exposure, which provides an opportunity for early preventative or
94	ameliorative interventions. Identification of biological correlates of PTSD symptom trajectories has
95	the potential to elucidate underlying biological mechanisms, stratify individuals according to relative
96	risk, target and track the efficacy of treatment, and enable more accurate assessment of novel
97	intervention strategies (Schultebraucks et al. 2021).

98

99 Aims of the systematic review

100 The aim of this systematic review is to summarise recent insights into the molecular aetiology and 101 pathophysiology of PTSD, identify key biological signatures involved, highlight methodological 102 advances, and provide an overview of the global nature, state, and representation of the research 103 field. We focussed on longitudinal studies, as they can more accurately capture the complex and 104 dynamic relationships between biological signatures and symptom trajectories and can assess the 105 role of potentially modifiable factors as moderators or mediators of risk. To provide a more in-depth 106 review, we additionally chose to focus on studies examining biological correlates as predictors of 107 PTSD risk or symptom trajectory, rather than treatment response.

108

109 <u>Methods</u>

110 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were employed111 in conducting the systematic review (Page et al. 2021).

112

113 Search strategy

114 Two researchers, JSW and MdP, independently searched the Pubmed, Scopus and Web of Science 115 databases on 9 September 2022 for manuscripts published since 1 January 2021 using the following 116 search terms: (("post-traumatic stress" [All Fields]) OR ("posttraumatic stress" [All Fields]) OR (PTSD [All Fields])) AND ((neurobiolog* [All Fields]) OR (genom* [All Fields]) OR (DNA [All Fields]) OR ("stress 117 118 hormone" [All Fields])) AND (English[Language]) NOT (animal). These terms were designed to 119 capture studies examining molecular correlates (including genomic, endocrine, and inflammatory 120 measures) of PTSD in human participants. The term 'trauma' was not included due to its high 121 overlap with studies in the fields of surgery, physical rehabilitation, and orthopaedics, which yield 122 datapoints outside the scope of the review. The search was repeated using the same strategy on 22 March 2023 to include articles published up until 31 December 2022. This two-year time frame was 123 124 chosen to focus on recent findings so that the review provides state-of-the-art insights into PTSD.

125

126 Eligibility criteria and selection process

127 The online open-source software Rayyan was used to collate the database search outputs, scan for 128 duplicates, and conduct preliminary selection of articles (Ouzzani et al. 2016). Suspected duplicate 129 articles flagged by the software were manually checked and removed if necessary. Selection of 130 publications was performed by applying inclusion and exclusion criteria to the study abstracts. 131 Studies to be included had to a) comprise original research manuscripts or meta-analyses of b) 132 cohort investigations that c) assessed longitudinal relationships between d) one or more molecular-133 level measures and e) either PTS symptoms or PTSD status, and f) be written in English. Exclusion criteria related to the manuscript type and research approach employed. Narrative reviews, case 134 135 studies and protocol papers, as well as studies of exclusively healthy participants exposed to an 136 experimental stressor or using animal models were excluded. The final study selection was based on 137 a review of the full text manuscripts. A third researcher was approached when inclusion decisions

- were discrepant, and a final decision was reached by consensus. A total of 18 manuscripts wereselected for the systematic review (Figure 1).
- 140

141 **Quality assessment**

The quality of each study was independently assessed by researchers (JSW, MCG, MdP) using the 142 Systematic Appraisal of Quality in Observational Research (Ross et al. 2011). This tool evaluates the 143 quality of evidence-based cohort and case-control observational studies in psychiatric research and 144 145 assesses quality across five categories, namely sample, control/comparison group, measurement 146 and output quality, follow-up, and distorting influences. The extent to which each study complies with the two to five statements listed under each category is used to classify quality as adequate, 147 148 unclear or inadequate. A final quality level ranging from low to high was assigned based on these 149 metrics.

150

151 Data extraction

152 Researchers (JSW, MdP, MCG) individually extracted data from articles using a template designed to 153 capture information relevant to the review aims. The study design and setting category reports on 154 the design, location of the study and/or site of participant recruitment, and the name of the parent 155 study or cohort if applicable. The sample characteristics category records the number, sex, age and ancestry of participants broken down according to experimental group or study cohorts if necessary. 156 157 The third category for data extraction was the overall stated aim of the study. Clinical measures 158 record the PTSD assessment instruments, while the type of molecular measure and source tissue 159 were included under molecular measures. The sixth category, primary findings, captured the main 160 outcomes of the stated study aims. Findings unrelated to the relationship between molecular 161 measures and PTSD were excluded. Extracted data are reported in Table 1.

162

- 163 <u>Results</u>
- 164 Study characteristics

165	Our search yielded 18 studies that examined longitudinal relationships between PTS/PTSD and
166	molecular biology measures with sample sizes ranging from 39 to 1135 participants. Study groups
167	were primarily comprised of military veterans/personnel (n = 4), individuals hospitalised following
168	traumatic injury (n = 4), or women exposed to interpersonal violence/trauma (n = 3) or rape (n = 3).
169	The Clinician-Administered PTSD Scale (n_{DSM-IV} = 5, n_{DSM-5} = 2), PTSD Checklist ($n_{Civilian version}$ = 3, n_{DSM-5} =
170	4, n_{DSM-IV} = 2), and Davidson Trauma Scale (n = 3) were the most commonly used measures with both
171	continuous scores and case-control status used as outcome variables. Genomic investigations were
172	the most frequently employed molecular measure and included gene expression (n = 2), genotype (n
173	= 9) and DNA methylation (n = 7) analyses that spanned candidate and whole-genome approaches.
174	Endocrine (n = 2) and inflammatory marker (n = 2) measures were also represented. Four of the
175	studies were performed in LMICs, of which three were conducted in South Africa. The majority of
176	upper-income country (UIC) studies were conducted in the USA (n = 10). Of the 15 studies that
177	reported on ancestry/ethnicity, White/European/Caucasian and African American/Black ancestry
178	were the sole or most prevalent ancestral grouping in seven studies each.

179

180 Molecular signatures of PTSD/PTS

181 *Candidate genotype or marker investigations*

182 Several studies employed candidate gene approaches. A study of mother-child dyads found that, in

- 183 children carrying the "risk" T allele of rs1360780, a variant found in the stress-related FKBP5 gene,
- 184 higher maternal PTS scores at baseline predicted more severe total and dissociation-related trauma

185	symptoms in children 9 months later. This relationship remained significant even when trauma
186	exposure in the children was controlled for (Pereira et al. 2021). Landoni et al. (2022) examined the
187	influence of the serotonin transporter long polymorphic region on the development of perinatal
188	PTSD assessed in the two months prior to birth (T1), as well as at 2-3 weeks (T2) and 3-4 months (T3)
189	postnatally. The lower expression SS polymorphism was associated with elevated T2 intrusive and T3
190	hyperarousal symptoms, and moderated the worsening of intrusive, hyperarousal and avoidance
191	symptoms from T1 to T3, intrusive symptoms between T1 and T2, and avoidance symptoms
192	between T2 and T3. Chen et al. (2022) found that the AA genotype of rs1800872, a single nucleotide
193	polymorphism (SNP) in the gene encoding the anti-inflammatory cytokine interleukin-10 (IL-10),
194	predicted PTSD symptom severity persistence between six and 18 months, as well as higher 18-
195	month PTSD scores, in male but not female students following earthquake exposure.
196	
197	In a study examining endocannabinoids, deRoon-Cassini et al. (2022) found that male and ancestry
198	minority (predominantly African) participants admitted to hospital following traumatic injury who
199	were homozygous for the A allele of the FAAH rs324420 SNP had higher baseline serum levels of N-
200	arachidonoylethanalomine compared to C allele carriers. Elevated N-arachidonoylethanalomine
201	positively predicted six- to eight-month follow-up PTSD status across participants and avoidance and
202	negative alterations of cognition and mood in female participants. Baseline circulating levels of 2-
203	arachidonoylglycerol predicted follow-up reexperiencing, arousal, and negative alterations to

204 cognition and mood symptoms in ancestry minority participants. Endocannabinoid signalling is stress

205 responsive and involved in a broad range of biological processes, such as neurotransmission,

206 synaptic plasticity, inflammation, and learning and memory, which may be relevant to PTSD

207 (deRoon-Cassini et al. 2022; Gorzkiewicz and Szemraj 2018). Vuong et al. sought to identify whether

208 the anti-inflammatory cytokine, adiponectin, may play a role in PTS symptom severity in women

209 following rape exposure. Of the eight SNPs in *ADIPOQ*, the gene encoding adiponectin, that were

210	investigated, only rs444174 was associated with symptom severity at three and six months though
211	this relationship did not remain significant when models were adjusted for covariates (Vuong,
212	Hemmings, et al. 2022). In a study that included the same rape-exposed participants, as well as
213	unexposed controls, lower baseline serum levels of adiponectin were associated with increased risk
214	of probable PTSD at six months across participants. However, this relationship did not hold true
215	when analyses were limited to women exposed to rape (Vuong, Mhlongo, et al. 2022).
216	
217	Polygenic risk score analyses
218	Tamman et al. (2022) found that that a higher polygenic risk score, an aggregate score reflecting
219	genetic predisposition liability, predicted increased risk for an incident positive PTSD screen at two-,
220	four- or seven-years in military veterans with an insecure attachment style. Of 30 genetic loci
221	significantly associated with PTSD, thirteen loci conferred risk or resilience based on patterns of
222	environmental features (trauma burden, age, sex, social and structural support, and combat status).
223	The strongest effect was seen for the rs4702 SNP in the gene encoding FURIN, which has been linked
224	to brain derived neurotrophic factor and matrix metalloproteinase signalling and plays a role in
225	synaptic plasticity, including in relation to fear and environmental adversity. Risk score gene sets
226	showed enrichment for immune function, specifically biological processes relevant to mast cells.
227	Drug repositioning based on gene ontology highlighted doxylamine, an antihistamine and
228	antimuscarinic that suppresses immune system activation and regulates sleep/wake cycles, as a
229	therapy for investigation.
230	
231	Epigenetic investigations
232	Several studies examined epigenetic mechanisms i.e., environmentally sensitive structural changes

to DNA conformation that can influence gene expression (Aristizabal et al. 2019). Hawn et al. (2022)

234 examined whether methylation in AIM2, a gene previously linked to inflammation, was associated 235 with PTSD symptom severity and mediated the relationship between PTSD symptomology and 236 markers of inflammation and neuropathology in a cohort of military veterans. The analyses indicated both time- and outcome-dependent effects of methylation. Lower methylation at the cg10636246 237 238 site mediated the baseline inverse association between PTSD symptom severity and the neuronal 239 damage marker neurofilament light chain. However, lower cg10636246 site methylation mediated a 240 positive association between symptom severity and proinflammatory (interleukin-6 and tumour 241 necrosis factor alpha) as well as anti-inflammatory cytokines (IL-10) at baseline, as well as an inverse 242 association between symptom severity and IL-10 two years later. Drawing on measures of social adversity, prior psychopathology and methylation in sites linked to the glucocorticoid receptor 243 244 response network, Wani et al. (2021) used machine learning (ML) to prospectively predict the risk of 245 high PTSD symptom severity in an adult cohort. Though prior PTS symptoms accounted for 88% of 246 the variance, CpG sites made up more than half of the top 150 model features and implicated stress 247 response and inflammatory mechanisms in PTSD risk. Notably, methylation at cg20509117 in IL-6 248 was among the 79 sites identified. In a study investing intergenerational effects of intimate partner 249 violence-associated PTSD, Cordero et al. (2022) aimed to assess correlations between maternal and 250 infant site- and region-level glucocorticoid receptor (NR3C1) methylation profiles and to determine 251 whether maternal methylation profiles predicted offspring internalising and externalising behaviours 252 measured four years later. The average methylation of thirteen glucocorticoid receptor promoter 253 region sites was significantly correlated between mothers and their infants only in the context of PTSD i.e., not in control mother-infant dyads. A lower maternal methylation profile predicted 254 255 increased externalising behaviour measured when children were of school-going age. These findings 256 suggest that epigenetic signatures related to stress responding may contribute to the 257 intergenerational effects of PTSD on mental health by biologically embedding adverse outcomes. In 258 a cohort of military personnel with pre- and post-deployment molecular and clinical data,

259 methylation at four sites and in 88 differentially methylated regions (DMRs) was associated with 260 baseline PTS symptom severity, whilst longitudinal analysis identified fifteen deployment-associated 261 DMRs (Katrinli et al. 2022). The two DMRs predicting both baseline and longitudinal PTS symptom severity were located near genes encoding OTUD5 and ELF4, which are involved in inflammatory and 262 263 oxidative stress processes. In a study investigating epigenetic signatures of PTSD following sexual 264 assault, Nöthling et al. (2021) identified that baseline methylation at an intergenic site near the 265 SLC16A9 gene was higher in rape-exposed women who met criteria for PTSD three months later. 266 Two of the 34 PTSD-associated DMRs were located in genes (BRSK2 and ADCYAP1) previously 267 implicated in mood or trauma-related disorders. BRSK2 is involved in neurotransmission and is highly 268 expressed in hippocampus, a brain region fundamental to learning and memory, while the protein 269 encoded by ADCYAP1 plays a key role in stress response regulation. Targeted methylation analyses 270 of regions in BRSK2 and ADCYAP1 was performed in a replication sample, and the longitudinal 271 associations between PTSD symptom and methylation profiles at baseline, three and six months in 272 both the discovery and replication samples was assessed. Of these follow-up analyses, only an association between changes from baseline to three months in PTSD symptom severity and 273 274 methylation at a *BRSK2* site remained significant after controlling for covariates.

275

276 Methylation data can be used to generate epigenetic clock estimates of biological aging i.e. wear and 277 tear that occurs over and above that due to chronological age (Horvath 2013). Accelerated biological 278 aging according to DNAm GrimAge, a clock sensitive to age-related morbidity and mortality, in 279 combat veterans was associated with PTSD status at baseline in both discovery and validation 280 cohorts, as well as PTSD symptom severity at baseline when the cohorts were combined. In a subset 281 of discovery cohort participants who completed assessments three years later, change in PTSD 282 symptom severity was positively correlated with change in age acceleration, with this relationship 283 primarily driven by symptoms in the hyperarousal cluster. The contribution of immune mechanisms

284	to advanced age acceleration is uncertain given that this biological aging metric was not associated
285	with circulating levels of five cytokines but was significantly associated with increased
286	immunosenescence based on CD8 and CD28 T lymphocyte proportions (Yang et al. 2021). A study of
287	paramedicine students also found evidence for a relationship between PTSD symptomology and
288	GrimAge estimates with both baseline and one-year GrimAge estimates positively associated with
289	PTSD symptom severity at one year (Mehta et al. 2022). Baseline epigenetic age acceleration, a
290	metric derived from the Horvarth algorithm, was positively associated with cross-sectional and
291	longitudinal PTSD symptom severity, whilst baseline, but not follow-up symptom severity, predicted
292	one-year epigenetic age acceleration.
293	
294	Studies employing multimodal data
295	Four studies utilised multilevel data. Schultebraucks et al. (2021) applied ML models to data
296	routinely collected on emergency room admission and in the two days thereafter (endocrine, trauma
297	phenotype, demographic, vital signs, pharmacotherapy, and injury and trauma characteristics) to
298	identify prognostic features for PTSD. The model identified that acute sympathetic nervous system
299	activity, cortisol levels and opiate medication prescription, in addition to age, prior trauma
300	experience and perceived impact of these events, perceived life threat, and amnesia predicted
301	longitudinal (one-, three-, six- and twelve-month) self-reported symptom severity and twelve-month
302	PTSD diagnosis. Three measures of thyroid function were among the fifteen strongest predictors,
303	suggesting a role for the hypothalamic-pituitary-thyroid axis. A particular strength of this study was
304	its use of routinely collected data, which provides a higher potential clinical utility. Lori et al. (2021)
305	found that baseline expression levels of GRIN3B, which encodes an NMDA glutamate receptor
306	subunit, in blood were significantly associated with PTS scores at one, three, six and twelve months
307	and showed a dose-dependent positive relationship with symptom trajectory (chronic vs. remitting

308 vs. resilient) in individuals admitted to hospital emergency units. The authors examined whether 309 methylation and expression quantitative trait loci i.e., loci where methylation or genetic variants, 310 respectively, influence gene expression, could explain the observed relationship between GRIN3B expression and risk for chronic PTSD. The analysis yielded no significant methylation quantitative 311 312 trait loci but four SNPs were identified as GRIN3B expression quantitative trait loci with the minor 313 allele of the rs10401454 SNP, which is associated with reduced expression, also associated with 314 resilience to PTSD in an independent study cohort. GRIN3B encodes a subunit of the NMDA 315 glutamate receptor, which may be upregulated in response to stress, and thus implicates 316 glutamatergic processes, such as fear conditioning in the development of PTS symptoms. 317 Furthermore, leukocyte expression of NMDA receptors suggests a tangential link to immune 318 mechanisms in PTSD via GRIN3B effects on NMDAR activity. The study drew on the Genotype-Tissue 319 Expression database to confirm that rs10401454 acts as an expression quantitative trait locus in 320 whole blood, cerebellum and basal ganglia tissue and that minor allele homozygosity is associated 321 with lower GRIN3B expression in cortex and frontal cortex. This indicates a degree of cross-tissue coherence and provides more confidence in inferring brain expression levels based on peripheral 322 323 tissue measures. Wuchty et al. (2021) collected multiomic data from participants immediately and 324 six months after trauma exposure. Based on the rationale that dynamic gene expression profiles 325 provide valuable biological insights and that transcriptomic signatures could act as an intermediate 326 phenotype, their study integrated genotype, transcriptomic and gene expression data. Using 327 directed network analysis to draw causal inferences, they identified thirteen genes that may drive 328 dysregulated gene expression underlying PTSD development. Key processes supported by these 329 genes related to threat processing and responding, and fear-related memory acquisition, 330 consolidation, and extinction. Morris et al. (2022) used multilevel modelling and ML to examine 331 demographic, cognitive, clinical and biological (diurnal and laboratory stressor-elicited cortisol and 332 alpha-amylase levels, as well as heart rate and hair cortisol) data to predict PTSD development at

333 one-, three- and six-month timepoints in young women exposed to interpersonal violence in the 334 three months prior to study initiation. These factors were not associated with baseline or 335 longitudinal PTS symptom severity using multilevel modelling but did improve ML model accuracy, suggesting that the stress response and acute sympathetic nervous system activity play an indirect 336 role in the development of PTSD. 337 338 339 **Quality appraisal** 340 All studies adequately described exposure and/or outcome measures, and most assessed potential 341 distorting influences and clearly delineated control or comparison groups where appropriate (Table 342 2). Limitations were noted in the categories related to the description of the sample and reporting 343 on data. Several studies had relatively modest sample sizes and most did not report on study power. 344 Given the cost of conducting molecular-level investigations, especially those that draw on omics 345 measures, this is not unexpected but does raise doubts as to whether the sample can be considered 346 representative of the source population. The number of potential covariates or confounding 347 influences assessed varied widely across studies. Imputation was frequently employed to address missing data, though several studies did not specifically address the presence/absence of missing 348 349 data or how this was handled. 350 351 Discussion 352 **Key findings**

353 Molecular profiles

354 Several key themes emerge from the study findings. First, converging lines of evidence support the 355 role of inflammatory/immune (Chen et al. 2022; Hawn et al. 2022; Katrinli et al. 2022; Tamman et al.

356 2022; Wani et al. 2021), stress response (Carleial et al. 2021; Cordero et al. 2022; Morris et al. 2022; 357 Pereira et al. 2021; Schultebraucks et al. 2021; Wani et al. 2021) and learning and memory processes 358 (Carleial et al. 2021; Lori et al. 2021; Tamman et al. 2022; Wuchty et al. 2021) in PTSD pathophysiology with exploratory hypothesis-generating approaches utilising whole genome 359 360 transcription, epigenetic and genotype data showing enrichment for these mechanisms. 361 Inflammatory processes may contribute to PTSD symptomology by affecting cognition, stress responding, and the structure and function of brain regions involved in affect, and learning and 362 363 memory (Kim, Lee, and Yoon 2020; Sumner et al. 2020). Two studies directly investigated 364 inflammatory mechanisms. Though the functional effects of the IL-10 SNP rs1800872 investigated by 365 Chen et al. (2022) is unknown, Hawn et al. (2022) found evidence that a more proinflammatory 366 environment may contribute to PTSD with higher circulating levels of proinflammatory cytokines and 367 lower levels of an anti-inflammatory cytokine predicting worse PTSD symptom severity at baseline 368 and two years, respectively. Inflammation is also reciprocally related to the activity of the 369 hypothalamus-pituitary-adrenal axis, which is activated upon threat perception, coordinates the 370 stress response, and may affect cognition and mood (Leistner and Menke 2020). The studies by 371 Pereira et al. (2021) and Cordero et al. (2022) directly assessed components of the stress response 372 system, namely FKBP5 rs1360780 genotype and NR3C1 methylation, respectively. Their findings 373 suggest that the sensitivity and number of glucocorticoid receptors, play a role in the 374 pathophysiology of PTSD. This, in addition to findings that including cortisol levels improves 375 predictive performance of ML models (Morris et al. 2022; Schultebraucks et al. 2021), is in keeping 376 with a substantial body of evidence indicating that dysregulation of the stress response is a key 377 component of PTSD pathophysiology (Fischer et al. 2021). Inflammation and stress responding can 378 accelerate biological aging and thus underlie the findings of increased epigenetic clock age estimates 379 in PTSD (Mehta et al. 2022; Wolf and Morrison 2017). Identification of processes related to synaptic 380 plasticity, and learning and memory may be explained by previous finding that individuals with PTSD

fail to restrict fear responses to the environment, context or cues that elicited the trauma. Instead,
overgeneralisation of fearful memories to non-specific targets, combined with reduced fear
extinction, can produce the symptoms of hyperarousal and intrusion characteristic of PTSD (Ressler
et al. 2022).

385

386 The studies included in this manuscript provide strong evidence for biological processes in PTS. 387 However, the capacity for these biological correlates to predict relative risk or symptom trajectory is 388 not clear. Though genotype investigations are beneficial in that they provide a static measure, PTSD 389 is a polygenic disorder and the contribution of individual variants is likely small (Nievergelt et al. 390 2019). Therefore, the results of targeted studies, such as those by Chen et al. (2022), Pereira et al. 391 (2021) and Landoni et al. (2022), which identified roles for specific variants in PTSD risk, may not 392 have sufficient discriminative capacity for clinical use. Polygenic risk scores, as generated in Tamman 393 et al. (2022), can explain more of the variance in outcome but do not necessarily perform well across 394 populations of different ancestry. This limitation to their use in global contexts is exacerbated by the 395 underrepresentation of diverse ancestries in psychiatric genetics research (Nievergelt et al. 2019). 396 Other genomic approaches also have limitations. Studies utilising epigenetic and transcriptomic data 397 report relative associations i.e., the analyses are based on comparisons within study groups and do 398 not provide set cut-off values that could be used to stratify individuals according to risk. Methylation 399 and transcriptomic measures can differ according to tissue type and cellular composition, the latter 400 of which most, but not all, of the studies reviewed stated that they controlled for. Studies also 401 indicated that the influence of biological mechanisms may depend on environmental as well as 402 demographic factors such as sex and ancestry (Chen et al. 2022; deRoon-Cassini et al. 2022; Tamman 403 et al. 2022). A further limitation in identifying biological correlates with potential clinical utility is 404 that PTSD can have diverse presentations with recent studies indicating the presence of multiple 405 typologies such as threat reactivity, low-symptom, high-symptom and dysphoric classes (Bucich,

406 Steel, and Berle 2022; Campbell et al. 2020). This phenotypic complexity may be mirrored in the 407 biological processes conferring risk for specific symptom clusters, as was seen in the studies by 408 Landoni et al. (2022), deRoon-Cassini et al. (2022) and Yang et al. (2021). Consequently, it is also 409 possible that existing and valid relationships between biological correlates and symptom typologies 410 were not discerned in studies that used only PTSD status and/or total symptom scores. Based on 411 these limitations, biological correlate research at present seems better able to inform on underlying 412 mechanisms than to stratify individuals according to risk and target preventative measures and 413 interventions.

414

415 Study contexts

416 Selected studies were mainly conducted in UICs and comprised predominantly Caucasian ancestry 417 participants, although those recruiting patients admitted to hospital emergency units and military 418 veterans/personnel reflected a more diverse ancestry profile. Despite being home to 84.5% of the 419 global population in 2021 ("World Development Indicators | The World Bank" n.d.), less than one 420 quarter of the selected studies were conducted in LMICs. These investigations reflect a more 421 constrained participant demographic profile (Black adult females or Chinese male and female 422 adolescents), range of trauma experiences (rape or earthquake exposure) and number of molecular 423 techniques employed (candidate gene, inflammatory marker or DNA methylation) than UIC studies. 424 None of the studies generating multimodal data or using ML or multilevel modelling were performed 425 in LMICs. Representation within LMIC studies was also unequal with three of four publications based 426 on a single South African cohort study examining outcomes of rape exposure in female participants 427 that identified as Black African. Our search criteria did not yield any studies conducted in South 428 American or South or South-East Asian populations. Furthermore, all but one study recruited adult 429 participants. This is problematic given that the age structure in LMICs is skewed towards younger

430 age categories and that trauma exposure occurring during sensitive windows of neurodevelopment 431 can have substantial effects on neurobiology and mental health risk across the lifespan (Herringa 432 2017). The treatment gap is higher in LMICs with treatment seeking rates in these countries only half that reported in UICs, and established risk factors for PTSD, including social disadvantage, younger 433 434 age, lower household income, unemployment and lower levels of education, are observed at 435 disproportionately higher rates in LMICs (Koenen et al. 2017). These LMIC vs UIC disparities 436 undermine efforts to address the global burden of PTSD. Understanding the interaction of 437 environmental and molecular neurobiological determinants in the genesis of PTSD is key to the 438 discovery of new and effective treatments, which has been highlighted as a particularly pressing need in LMICs. However, the potential for biological mechanisms to inform preventative and 439 440 therapeutic measures will only be realised if the number and scope of studies more closely aligns 441 with the global burden of trauma and PTSD.

442

443 Study approaches

444 Several studies integrated multimodal data which can provide comprehensive and deep insights into 445 psychiatric outcomes (Wuchty et al. 2021). Studies made use of sophisticated analyses, including ML 446 and multilevel modelling. The former does not test specific hypotheses but rather learns which 447 combination of features best predicts outcomes and, by including variable interrelationships, can 448 account for indirect contributions to outcomes. In contrast, multilevel modelling assesses how variables are related and can thus provide a more interpretable, but potentially less accurate, model 449 450 (Morris et al. 2022). Unfortunately, the cost of collecting multilevel data limits study replication and 451 sample size, the latter of which reduces the likelihood of adequately representing the source 452 population or conducting sex-, age- or ancestry-stratified analyses. Therefore, it is important that 453 LMICs are included in psychiatric genetic and other consortia of multi-country investigators and

454 studies. Despite relatively small sample sizes, omics studies can increasingly draw on available public 455 and consortia databases to interpret and gain functional insights into data. Examples include functional enrichment for biological processes and information on tissue-specific gene expression. 456 The latter is particularly useful in neuroscience, where the inaccessibility of brain tissue necessitates 457 458 inferences about neural mechanisms based on peripheral tissues. Though the results obtained from 459 multiomics studies are informative, their clinical utility is low insofar as they rely on data that is not 460 routinely collected from or available for individuals seeking post-trauma care (Schultebraucks et al. 461 2021).

462

463 Limitations

464 This review has several limitations. We selected a narrow publication timeframe and limited our 465 selection to longitudinal studies reporting results in English. This excludes insights offered by studies 466 published in other languages and by cross-sectional investigations, and may have limited the representation of selected studies. Though the number of publications fitting our search terms is 467 468 increasing year-on-year (Figure 2), it is not possible to discern whether this is true for both UICs and 469 LMICs, or to draw inferences about trends in methodological approaches. The narrow timeframe, as 470 well as the impact of COVID-19, could also have exaggerated the fault line between published 471 research in UICs and LMICs. Our focus on molecular-level aetiology only reflects a subset of biological mechanisms and ignores findings from neuroimaging and psychophysiological studies. We 472 473 did not report on animal model investigations, which have the potential to unravel causal mechanisms, as opposed to the correlative associations identified in human studies. We also did not 474 475 conduct a meta-analysis of study findings. Finally, we did not consider the full range of trauma-476 associated adverse outcomes or the contribution of molecular profiles to cross-disorder risk.

478 <u>Conclusions</u>

479	The potential benefits of biological insights into PTSD are compelling with recent research identifying
480	inflammatory, stress response, and learning and memory processes in PTSD pathophysiology. The
481	sophistication and scope of molecular techniques and data analytic approaches are rapidly
482	expanding. However, greater representation of LMICs in research is required for biological insights
483	to reduce the global burden of PTSD and associated adverse effects on health and wellbeing.
484	
485	Author contribution statement
486	JSW: Conceptualisation, investigation, data curation, writing - original draft, writing – review and
487	editing
488	MdP: Investigation, data curation, writing - original draft, writing – review and editing
489	MCG: Investigation, data curation, writing - original draft, writing – review and editing
490	LLvdH: Conceptualisation, writing – review and editing
491	EK: Writing – review and editing
492	SS: Conceptualisation, writing – review and editing
493	
494	Financial support
495	Research reported in this publication was partly supported by the South African Medical Research
496	Council. MCG was supported by a Career Development Award from the U.S. National Institute of
497	Mental Health (K01MH129572).

499	Conflicts of interest statement
500	Conflicts of Interest: None
501	
502	Ethics statement
503	All authors declare that they have adhered to the publishing ethics of Global Mental Health.
504	
505	Data availability statement
506	A systematic review of published literature was performed. No original research data were
507	generated.
508	
509	References
510	American Psychiatric Association, ed. 2013. Diagnostic and Statistical Manual of Mental Disorders:
511	DSM-5. 5th ed. Washington, D.C: American Psychiatric Association.
512	Aristizabal, Maria J., Ina Anreiter, Thorhildur Halldorsdottir, Candice L. Odgers, Thomas W. McDade,
513	Anna Goldenberg, Sara Mostafavi, et al. 2019. "Biological Embedding of Experience: A
514	Primer on Epigenetics." Proceedings of the National Academy of Sciences of the United
515	States of America, October. https://doi.org/10.1073/pnas.1820838116.
516	Benjet, C., E. Bromet, E. G. Karam, R. C. Kessler, K. A. McLaughlin, A. M. Ruscio, V. Shahly, et al. 2016.
517	"The Epidemiology of Traumatic Event Exposure Worldwide: Results from the World Mental
518	Health Survey Consortium." Psychological Medicine 46 (2): 327–43.
519	https://doi.org/10.1017/S0033291715001981.

520	Bucich, Micaela, Zachary Steel, and David Berle. 2022.	"Posttraumatic Stress Disorder (PTSD)
-----	--	---------------------------------------

- 521 Symptom Profiles among People Who Have Experienced Abuse: Findings from the NESARC-
- 522 III Study." Psychological Trauma: Theory, Research, Practice, and Policy, No Pagination

523 Specified-No Pagination Specified. https://doi.org/10.1037/tra0001193.

- 524 Campbell, Sarah B., Benjamin Trachik, Simon Goldberg, and Tracy L. Simpson. 2020. "Identifying
- 525 PTSD Symptom Typologies: A Latent Class Analysis." *Psychiatry Research* 285 (March):

526 112779. https://doi.org/10.1016/j.psychres.2020.112779.

- 527 Carleial, Samuel, Daniel Nätt, Eva Unternährer, Thomas Elbert, Katy Robjant, Sarah Wilker, Vanja
- 528 Vukojevic, Iris-Tatjana Kolassa, Anja C. Zeller, and Anke Koebach. 2021. "DNA Methylation
- 529 Changes Following Narrative Exposure Therapy in a Randomized Controlled Trial with

530 Female Former Child Soldiers." *Scientific Reports* 11 (1): 18493.

531 https://doi.org/10.1038/s41598-021-98067-9.

532 Cassini, Terri A. deRoon-, Carisa L. Bergner, Samantha A. Chesney, Nicholas R. Schumann, Tara

533 Sander Lee, Karen J. Brasel, and Cecilia J. Hillard. 2022. "Circulating Endocannabinoids and

- 534 Genetic Polymorphisms as Predictors of Posttraumatic Stress Disorder Symptom Severity:
- 535 Heterogeneity in a Community-Based Cohort." *Translational Psychiatry* 12 (1): 48.

536 https://doi.org/10.1038/s41398-022-01808-1.

537 Charlson, Fiona, Mark van Ommeren, Abraham Flaxman, Joseph Cornett, Harvey Whiteford, and

538 Shekhar Saxena. 2019. "New WHO Prevalence Estimates of Mental Disorders in Conflict

539 Settings: A Systematic Review and Meta-Analysis." *The Lancet* 394 (10194): 240–48.

540 https://doi.org/10.1016/S0140-6736(19)30934-1.

- 541 Chen, Yong Li, Yan Jiang Zheng, Yi Lin Shen, Qi Wei Guo, Xu Chen, Jia Lin, and Ding Zhi Fang. 2022.
- 542 "Male Adolescents with Interleukin 10 Rs1800872 AA Genotype Had Higher Prevalence and
- 543 Slower Recoveries of Post-Traumatic Stress Disorder at Late Stage of a Follow-Up."
- 544 *Neuroscience Letters* 771 (February): 136411. https://doi.org/10.1016/j.neulet.2021.136411.

- 545 Cordero, María I., Ludwig Stenz, Dominik A. Moser, Sandra Rusconi Serpa, Ariane Paoloni-Giacobino,
- 546 and Daniel Scott Schechter. 2022. "The Relationship of Maternal and Child Methylation of
- 547 the Glucocorticoid Receptor NR3C1 during Early Childhood and Subsequent Child
- 548 Psychopathology at School-Age in the Context of Maternal Interpersonal Violence-Related
- 549 Post-Traumatic Stress Disorder." *Frontiers in Psychiatry* 13 (August): 919820.
- 550 https://doi.org/10.3389/fpsyt.2022.919820.
- 551 Fischer, Susanne, Tabea Schumacher, Christine Knaevelsrud, Ulrike Ehlert, and Sarah Schumacher.
- 552 2021. "Genes and Hormones of the Hypothalamic-Pituitary-Adrenal Axis in Post-Traumatic
- 553 Stress Disorder. What Is Their Role in Symptom Expression and Treatment Response?"
- 554 Journal of Neural Transmission (Vienna, Austria: 1996) 128 (9): 1279–86.
- 555 https://doi.org/10.1007/s00702-021-02330-2.
- Gorzkiewicz, Anna, and Janusz Szemraj. 2018. "Brain Endocannabinoid Signaling Exhibits Remarkable
 Complexity." *Brain Research Bulletin* 142 (September): 33–46.
- 558 https://doi.org/10.1016/j.brainresbull.2018.06.012.
- 559 Hawn, Sage E., Zoe Neale, Erika J. Wolf, Xiang Zhao, Meghan Pierce, Dana Fein-Schaffer, William
- 560 Milberg, Regina McGlinchey, Mark Logue, and Mark W. Miller. 2022. "Methylation of the
- 561 AIM2 Gene: An Epigenetic Mediator of PTSD-related Inflammation and Neuropathology
- 562 Plasma Biomarkers." *Depression and Anxiety* 39 (4): 323–33.
- 563 https://doi.org/10.1002/da.23247.
- 564 Herringa, Ryan J. 2017. "Trauma, PTSD and the Developing Brain." Current Psychiatry Reports 19
- 565 (10): 69. https://doi.org/10.1007/s11920-017-0825-3.
- 566 Hoppen, Thole H, Stefan Priebe, Inja Vetter, and Nexhmedin Morina. 2021. "Global Burden of Post-
- 567 Traumatic Stress Disorder and Major Depression in Countries Affected by War between 1989
- and 2019: A Systematic Review and Meta-Analysis." *BMJ Global Health* 6 (7): e006303.
- 569 https://doi.org/10.1136/bmjgh-2021-006303.

- 570 Horvath, Steve. 2013. "DNA Methylation Age of Human Tissues and Cell Types." *Genome Biology* 14
- 571 (10): R115. https://doi.org/10.1186/gb-2013-14-10-r115.
- 572 Katrinli, Seyma, Adam X. Maihofer, Agaz H. Wani, John R. Pfeiffer, Elizabeth Ketema, Andrew
- 573 Ratanatharathorn, Dewleen G. Baker, et al. 2022. "Epigenome-Wide Meta-Analysis of PTSD
- 574 Symptom Severity in Three Military Cohorts Implicates DNA Methylation Changes in Genes
- 575 Involved in Immune System and Oxidative Stress." *Molecular Psychiatry* 27 (3): 1720–28.
- 576 https://doi.org/10.1038/s41380-021-01398-2.
- 577 Kim, Tammy D., Suji Lee, and Sujung Yoon. 2020. "Inflammation in Post-Traumatic Stress Disorder
- 578 (PTSD): A Review of Potential Correlates of PTSD with a Neurological Perspective."
- 579 *Antioxidants* 9 (2): 107. https://doi.org/10.3390/antiox9020107.
- 580 Koenen, K. C., A. Ratanatharathorn, L. Ng, K. A. McLaughlin, E. J. Bromet, D. J. Stein, E. G. Karam, et
- al. 2017. "Posttraumatic Stress Disorder in the World Mental Health Surveys." *Psychological Medicine* 47 (13): 2260–74. https://doi.org/10.1017/S0033291717000708.
- 583 Landoni, Marta, Sara Missaglia, Daniela Tavian, Chiara Ionio, and Paola Di Blasio. 2022. "Influence of
- 584 5-HTTLPR Polymorphism on Postpartum Depressive and Posttraumatic Symptoms."
- 585 *Psychiatric Genetics* 32 (1): 9–14. https://doi.org/10.1097/YPG.00000000000299.
- 586 Leistner, Carolin, and Andreas Menke. 2020. "Chapter 4 Hypothalamic–Pituitary–Adrenal Axis and
- 587 Stress." In Handbook of Clinical Neurology, edited by Rupert Lanzenberger, Georg S. Kranz,
- 588 and Ivanka Savic, 175:55–64. Sex Differences in Neurology and Psychiatry. Elsevier.
- 589 https://doi.org/10.1016/B978-0-444-64123-6.00004-7.
- 590 Lori, Adriana, Katharina Schultebraucks, Isaac Galatzer-Levy, Nikolaos P. Daskalakis, Seyma Katrinli,
- 591 Alicia K. Smith, Amanda J. Myers, et al. 2021. "Transcriptome-Wide Association Study of
- 592 Post-Trauma Symptom Trajectories Identified GRIN3B as a Potential Biomarker for PTSD
- 593 Development." *Neuropsychopharmacology* 46 (10): 1811–20.
- 594 https://doi.org/10.1038/s41386-021-01073-8.

- 595 Mehta, Divya, Dagmar Bruenig, John Pierce, Anita Sathyanarayanan, Rachel Stringfellow, Olivia
- 596 Miller, Amy B. Mullens, and Jane Shakespeare-Finch. 2022. "Recalibrating the Epigenetic
- 597 Clock after Exposure to Trauma: The Role of Risk and Protective Psychosocial Factors."
- 598 Journal of Psychiatric Research 149 (May): 374–81.
- 599 https://doi.org/10.1016/j.jpsychires.2021.11.026.
- 600 Morris, Matthew C., Francisco Sanchez-Sáez, Brooklynn Bailey, Natalie Hellman, Amber Williams,
- 501 Julie A. Schumacher, and Uma Rao. 2022. "Predicting Posttraumatic Stress Disorder Among
- 602 Survivors of Recent Interpersonal Violence." *Journal of Interpersonal Violence* 37 (13–14):
- 603 NP11460–89. https://doi.org/10.1177/0886260520978195.
- Newnham, Elizabeth A., Enrique L. P. Mergelsberg, Yanyu Chen, Yoshiharu Kim, Lisa Gibbs, Peta L.
- 605 Dzidic, Makiko Ishida DaSilva, et al. 2022. "Long Term Mental Health Trajectories after
- 606 Disasters and Pandemics: A Multilingual Systematic Review of Prevalence, Risk and
- 607 Protective Factors." *Clinical Psychology Review* 97 (November): 102203.
- 608 https://doi.org/10.1016/j.cpr.2022.102203.
- 609 Nievergelt, Caroline M., Adam X. Maihofer, Torsten Klengel, Elizabeth G. Atkinson, Chia-Yen Chen,
- 610 Karmel W. Choi, Jonathan R. I. Coleman, et al. 2019. "International Meta-Analysis of PTSD
- 611 Genome-Wide Association Studies Identifies Sex- and Ancestry-Specific Genetic Risk Loci."
- 612 *Nature Communications* 10 (1): 1–16. https://doi.org/10.1038/s41467-019-12576-w.
- Nöthling, Jani, Naeemah Abrahams, Sylvanus Toikumo, Matthew Suderman, Shibe Mhlongo, Carl
- 614 Lombard, Soraya Seedat, and Sian Megan Joanna Hemmings. 2021. "Genome-Wide
- 615 Differentially Methylated Genes Associated with Posttraumatic Stress Disorder and
- 616 Longitudinal Change in Methylation in Rape Survivors." *Translational Psychiatry* 11 (1): 594.
- 617 https://doi.org/10.1038/s41398-021-01608-z.

- 618 Ouzzani, Mourad, Hossam Hammady, Zbys Fedorowicz, and Ahmed Elmagarmid. 2016. "Rayyan—a
- 619 Web and Mobile App for Systematic Reviews." *Systematic Reviews* 5 (1): 210.
- 620 https://doi.org/10.1186/s13643-016-0384-4.
- 621 Page, Matthew J, Joanne E McKenzie, Patrick M Bossuyt, Isabelle Boutron, Tammy C Hoffmann,
- 622 Cynthia D Mulrow, Larissa Shamseer, et al. 2021. "The PRISMA 2020 Statement: An Updated
- 623 Guideline for Reporting Systematic Reviews." *BMJ*, March, n71.
- 624 https://doi.org/10.1136/bmj.n71.
- 625 Pereira, Destiny M.B. Printz, Damion J. Grasso, Colin A. Hodgkinson, Kimberly J. McCarthy, Lauren S.
- 626 Wakschlag, and Margaret J. Briggs-Gowan. 2021. "Maternal Posttraumatic Stress and FKBP5
- 627 Genotype Interact to Predict Trauma-Related Symptoms in Preschool-Age Offspring." Journal
- 628 *of Affective Disorders* 292 (September): 212–16. https://doi.org/10.1016/j.jad.2021.05.042.
- 629 Purgato, Marianna, and Miranda Olff. 2015. "Global Mental Health and Trauma: The Current
- 630 Evidence and the Long Road Ahead." European Journal of Psychotraumatology 6
- 631 (November): 10.3402/ejpt.v6.30120. https://doi.org/10.3402/ejpt.v6.30120.
- 632 Ressler, Kerry J., Sabina Berretta, Vadim Y. Bolshakov, Isabelle M. Rosso, Edward G. Meloni, Scott L.
- 633 Rauch, and William A. Carlezon. 2022. "Post-Traumatic Stress Disorder: Clinical and
- 634 Translational Neuroscience from Cells to Circuits." Nature Reviews. Neurology 18 (5): 273–
- 635 88. https://doi.org/10.1038/s41582-022-00635-8.
- Ross, L. E., S. Grigoriadis, L. Mamisashvili, G. Koren, M. Steiner, C.-L. Dennis, A. Cheung, and P.
- 637 Mousmanis. 2011. "Quality Assessment of Observational Studies in Psychiatry: An Example
- 638 from Perinatal Psychiatric Research." International Journal of Methods in Psychiatric
- 639 *Research* 20 (4): 224–34. https://doi.org/10.1002/mpr.356.
- 640 Schultebraucks, Katharina, Marit Sijbrandij, Isaac Galatzer-Levy, Joanne Mouthaan, Miranda Olff, and
- 641 Mirjam van Zuiden. 2021. "Forecasting Individual Risk for Long-Term Posttraumatic Stress
- 642 Disorder in Emergency Medical Settings Using Biomedical Data: A Machine Learning

- 643 Multicenter Cohort Study." Neurobiology of Stress 14 (May): 100297.
- 644 https://doi.org/10.1016/j.ynstr.2021.100297.
- 645 Sumner, Jennifer A., Kristen M. Nishimi, Karestan C. Koenen, Andrea L. Roberts, and Laura D.
- 646 Kubzansky. 2020. "Posttraumatic Stress Disorder and Inflammation: Untangling Issues of
- 647 Bidirectionality." *Biological Psychiatry* 87 (10): 885–97.
- 648 https://doi.org/10.1016/j.biopsych.2019.11.005.
- Tamman, Amanda J.F., Frank R. Wendt, Gita A. Pathak, John H. Krystal, Steven M. Southwick, Lauren
- 650 M. Sippel, Joel Gelernter, Renato Polimanti, and Robert H. Pietrzak. 2022. "Attachment Style
- 651 Moderates Polygenic Risk for Incident Posttraumatic Stress in U.S. Military Veterans: A 7-
- 652 Year, Nationally Representative, Prospective Cohort Study." *Biological Psychiatry* 91 (7):
- 653 637–46. https://doi.org/10.1016/j.biopsych.2021.09.025.
- Vuong, Eileen, Sian Megan Hemmings, Shibe Mhlongo, Esnat Chirwa, Carl Lombard, Nasheeta Peer,
- 655 Naeemah Abrahams, and Soraya Seedat. 2022. "Adiponectin Gene Polymorphisms and
- 656 Posttraumatic Stress Disorder Symptoms among Female Rape Survivors: An Exploratory
- 657 Study." *European Journal of Psychotraumatology* 13 (2): 2107820.
- 658 https://doi.org/10.1080/20008066.2022.2107820.
- Vuong, Eileen, Shibe Mhlongo, Esnat Chirwa, Carl Lombard, Nasheeta Peer, Sian Megan Hemmings,
- 660 Naeemah Abrahams, and Soraya Seedat. 2022. "Serum Adiponectin-Levels Are Predictive of
- 661 Posttraumatic Stress Disorder in Women." *Neurobiology of Stress* 20 (September): 100477.
- 662 https://doi.org/10.1016/j.ynstr.2022.100477.
- 663 Wani, Agaz H., Allison E. Aiello, Grace S. Kim, Fei Xue, Chantel L. Martin, Andrew Ratanatharathorn,
- 664 Annie Qu, et al. 2021. "The Impact of Psychopathology, Social Adversity and Stress-Relevant
- 665 DNA Methylation on Prospective Risk for Post-Traumatic Stress: A Machine Learning
- 666 Approach." Journal of Affective Disorders 282 (March): 894–905.
- 667 https://doi.org/10.1016/j.jad.2020.12.076.

- 668 Wolf, Erika J., and Filomene G. Morrison. 2017. "Traumatic Stress and Accelerated Cellular Aging:
- 669 From Epigenetics to Cardiometabolic Disease." *Current Psychiatry Reports* 19 (10): 75.
- 670 https://doi.org/10.1007/s11920-017-0823-5.
- 671 "World Development Indicators | The World Bank." n.d. Accessed March 16, 2023.
- 672 http://wdi.worldbank.org/table/2.1.
- 673 Wuchty, Stefan, Amanda J. Myers, Manuel Ramirez-Restrepo, Matthew Huentelman, Ryan Richolt,
- 674 Felicia Gould, Philip. D. Harvey, et al. 2021. "Integration of Peripheral Transcriptomics,
- 675 Genomics, and Interactomics Following Trauma Identifies Causal Genes for Symptoms of
- 676 Post-Traumatic Stress and Major Depression." *Molecular Psychiatry* 26 (7): 3077–92.
- 677 https://doi.org/10.1038/s41380-021-01084-3.
- 678 Yang, Ruoting, Gwyneth W. Y. Wu, Josine E. Verhoeven, Aarti Gautam, Victor I. Reus, Jee In Kang,
- 579 Janine D. Flory, et al. 2021. "A DNA Methylation Clock Associated with Age-Related Illnesses
- 680 and Mortality Is Accelerated in Men with Combat PTSD." *Molecular Psychiatry* 26 (9): 4999–
- 681 5009. https://doi.org/10.1038/s41380-020-0755-z.

683 <u>Tables</u>

684 Table 1: Data extracted from studies examining the molecular contribution to PTSD

Study	Design and setting	Sample characteristics				Aims	Clinical	Molecular	Primary findings
		Sample size	Age	Sex (female)	Ancestry/ethnicit y		measures	measures	
Chen et al. (2022)	Longitudinal study of Chinese high school students following the Wenchuan earthquake	n = 462	Grades 11 & 12	57%	Not specified	To examine the longitudinal associations between PTSD, environmental factors, and IL-10 rs1800872 genotype	PCL-C at 6-, 12- and 18- months post exposure	IL-10 rs1800872 determined using DNA extracted from whole blood 6 months post exposure	Male AA homozygous participants had higher PTSD prevalence relative to male C allele carriers at 18 months. The prevalence of PTSD in the sample reduced from 6 to 18 months, except among males carrying the AA genotype. Patterns of PCL-C scores were associated with genotype
Coredero et al. (2022)	Swiss prospective longitudinal study of mothers exposed to interpersonal violence and their children recruited to the Geneva Early Childhood Stress Study	DNA methylation group n _{Total} = 48 mother-child dyads n _{PTSD} = 26 mother-child dyads <u>DNA</u> methylation and child behaviour group	Children at baseline: 27.8 ± 8.8 months Children at follow-up: 7.5 ± 0.95 years	Mothers: 100% Children: 69.4%	Not specified but recruitment in Switzerland with French language proficiency required	To examine NR3C1 methylation in mothers with interpersonal violence- associated PTSD and their children, and to investigate the relationship between maternal	CAPS-IV (mother)	Bisulphite pyrosequencing of DNA extracted from saliva collected from mothers and their 12-42 month-old children. Control for sample cell composition not reported.	Infant and maternal NR3C1 methylation is significantly correlated only in mothers with a diagnosis of PTSD. Lower maternal methylation predicted later increased externalising behaviours in

		n = 36				methylation			children at 5-9 vears
		mother-child				profile and child			of age.
		dvads				psychopathology			
deRoon- Cassini et al. (2022)	Prospective longitudinal study of adults hopsitalised following traumatic injury in the USA	n = 170	42.8 ± 16.5 years	31%	Caucasian 47.1%, Black American 44.1%, Hispanic/Latinx 7.6%, American Indian/Alaskan Native 1.2%	To examine associations between endocannabinoi d levels, genetic polymorphisms, and PTSD in adults hospitalised for traumatic injury	CAPS-5 and PCL-5 at baseline and 6-8 months follow-up	FAAH rs324420 genotype measured in DNA extracted from whole blood. Circulating endocannabinoi d and cortisol levels measured in serum at baseline and 6-8 months follow- up	Higher levels of AEA were associated with higher PTSD symptom levels at follow-up. Higher levels of 2-AG were associated with higher PTSD symptom levels at follow-up among minorities only. The rs324420 AA genotype was associated with higher PTSD symptom levels in Black participants only.
Hawn et al. (2022)	Cross-sectional and longitudinal study of US military veterans recruited to the TRACTS study	<u>Cross-</u> <u>sectional</u> n = 478 <u>Longitudinal</u> n = 296	<u>Cross-</u> <u>sectional</u> 32.92 ± 8.81 years <u>Longitudinal</u> 33.25 ± 9.20 years	<u>Cross-</u> <u>sectional</u> 9.6% <u>Longitudina</u> <u>I</u> 9.8%	Cross-sectional White 74%, Black/African American 9%, Asian 3%, American Indian/Alaska Native <1%, Hawaiian/other Pacific Islander <1%, Unknown 15%, Longitudinal White 74%, Black/African American 10%, Asian 2%, American Indian/Alaska	To determine whether <i>AIM2</i> methylation mediates the cross-sectional and longitudinal relationships between PTSD symptom severity and peripheral markers of inflammation and neuropathology at baseline and 2-year follow-up	CAPS-IV / CAPS-5 at baseline and 2-year follow-up.	AIM2 methylation assessed using DNA extracted from blood. Cellular heterogeneity was accounted for in analyses. Measurement of 7 peripheral markers of neuropathology (NfL, GFAP, tau, Aβ40, Aβ42, pNfH and NSE). 5 inflammatory markers: IL-6, IL-	AIM2 methylation mediated the relationships between PTSD symptom severity and peripheral markers of inflammation (IL-10, IL-6, and TNFα) and neuropathology (NfL and GFAP) at baseline. PTSD symptom severity positively associated with levels of IL-6 and CRP and inversely associated with cg10636246

					Native <1%, Hawaiian/other Pacific Islander <1%, Unknown 16%			10, eotaxin, TNF α and CRP. Measurements performed at baseline and approximately 2 years follow-up.	methylation at baseline. AIM2 methylation mediated the association between baseline PTSD symptom severity and follow-up II-10.
Katrinli et al. (2022)	Longitudinal meta- analysis study of participants sourced from three military cohorts: MRS (USA), Army STARRS (USA) and PRISMO (Netherlands)	n _{Total} = 429 n _{PTSD} = 199 n _{Controls} = 230	MRS: 22.06 ± 2.24 STARRS: 24.47 ± 4.84 PRISMO: 27.35 ± 9.06	0%	Total: 77% European ancestry MRS: European 69.3%, African American 3.9%, Latino 12.6%, East Asian 1.6%, other 12.6% STARRS: European 67.4%, African American 11.4%, other 21.2% PRISMO: European 100%	To conduct a meta-analysis assessing epigenome-wide methylation changes associated with PTSD symptom severity pre and post deployment, and to identify DNA methylation profiles associated with baseline and longitudinal PTS symptom severity in military personnel	MRS: 17- item PCL-IV pre and post deploymen t Army STARRS: 6- item PCL pre and 17- item PCL-IV post deploymen t PRISMO: SRIP pre and post deploymen t	Genome-wide DNA methylation assessed in DNA extracted from whole blood. Cellular heterogeneity was accounted for in analyses.	4 DMPs and 88 DMRs were associated with PTSD symptom severity. Change in 15 DMRs were associated with change in PTSD symptom severity.
Landoni et al. (2022)	Longitudinal study of perinatal depressive and PTSD symptoms in Italian women	n _{enrolled} = 155 n _{prenatal} = 141 n _{postnatal1} = 127 n _{postnatal2} = 110	33.37 ± 4.64 years	100%	100% Caucasian	To examine the association between the 5- HTTLPR polymorphism and the development of perinatal depressive and PTSD symptoms	LASC prenatally, and LASC and PPQ at 2-3 weeks and 3 months postnatal	<i>5HTTP-LPR</i> polymorphism assessed in DNA extracted from whole blood or saliva	The SS genotype was associated with worse PTSD symptom severity at 2-3 weeks and 2-3 months postpartum.

Lori et al. (2021)	Prospective longitudinal cohort study of participants admitted to the Atlanta Grady Memorial hospital Emergency Department in the USA	$\frac{PTSD}{trajectory}$ $\frac{analysis}{n_{Total} = 224}$ $n_{Resilient} = 130$ $n_{Chronic} = 23$ $n_{Remitting} = 71$ $\frac{Trascriptomi}{c \ analysis}$ $n_{Total} = 153$ $n_{Chronic} = 23$ $n_{Resilient} = 130$	$\begin{tabular}{ c c c c } \hline PTSD \\ \hline trajectory \\ \hline analysis \\ \hline Total: 35.8 \pm \\ 12.5 years \\ Resilient: 35.9 \\ + 12.4 \\ \hline Chronic: 34.6 \\ + 11.2 \\ \hline Remitting: \\ 36.0 \pm 13.2 \\ \hline Transcriptomi \\ \hline c analysis \\ \hline Chronic: 34.6 \\ + 11.2 \\ \hline Resilient: 35.9 \\ + 12.4 \\ \end{tabular}$	Total: 50.9% Resilient: 47.7% Chronic: 60.9% Remitting: 53.5%	Total: African 71.4%, European 19.6%, other 8.9% Resilient: African 67.7%, European 22.3%, other 10% Chronic: African 73.9%, European 13%, other 13% Remitting: African 77.5%, European 16.9%, other 5.6%	To determine whether blood- based transcriptomic biomarkers collected shortly after an index trauma could predict PTSD symptom trajectories over subsequent months	PSS-I at 1, 3, 6 and 12 months	Transcriptome, eQTLs and meQTLs assessed in DNA extracted from whole blood at baseline. Cellular heterogeneity was accounted for in analyses.	Expression of GRIN3B and AMOTL1 , differed between chronic and resilient PTSD trajectories. The finding of low GRIN3B expression as a predictor of resilience survived Bonferroni multiple testing correction and subsequent adjustment for drug use, alcohol and education.
Mehta et al. (2022)	Cross-sectional and longitudinal study of paramedicine students in Australia	n = 39	23.44 ± 1.08 years (mean ± standard error)	61.50%	Caucasian 89.7%	To investigate biological aging using epigenetic clocks in relation to trauma exposure, and to examine environmental factors influencing this relationship	PCL-5 at baseline and 1 year	DNAm GrimAge, Horvath and BloodSkinAge epigenetic clocks measured using whole-genome methylation data assessed in DNA extracted from saliva collected at baseline and 1 year. Cellular heterogeneity was accounted for in analyses.	Epigenetic age acceleration and GrimAge are positively associated with PTSD symptom severity at baseline and follow-up. Epigenetic age acceleration and GrimAge at follow-up are associated with cluster D symptoms.
Morris et al. (2022)	Longitudinal predictive study of young women in the USA with past 3-month experience of	$n_{Total} = 58$ $n_{PTSD} = 7$ $nC_{ontrols} = 51$	With PTSD at 6 months: 25.0 ± 2.0 Without PTSD at 6 months: 23.7 ± 3.4	100%	White/Caucasian 57%, Black/African American 33%, Asian 10%, Hispanic 7%	To construct biopsychosocial variable-based ML models to predict PTSD symptom trajectories and	CAPS-IV at baseline, 1, 3 and 6 months	Diurnal and Trier Social Stress Test-elicited levels of cortisol and alpha amylase in saliva, and hair	Diurnal and Trier Social Stress Test- elicited cortisol and alpha amylase and hair cortisol were not associated with PTSD symptom trajectory

	interpersonal					end-point PTSD		cortisol collected	in multilevel models
	violence					status over a six-		at baseline	but did improve
						month period			predictive accuracy
									of ML models.
Nöthling et al.	Cross-sectional and	Discovery	Discovery	100%	Black African	To identify PTSD-	DTS at	Epigenome-wide	Cross-sectional
(2021)	longitudinal study	n _{Total} = 48	25.9 ± 5.4		100%	associated	baseline, 3	methylation	analysis in discovery
	examining	$n_{PTSD} = 24$	years			methylation	and 6	using DNA	cohort identifies 1
	epigenome-wide	Replication	Replication			profiles in rape-	months	extracted from	DMP (cg01700569)
	(discovery sample)	n _{total} = 96	24.6 ± 5.5			exposed women;		blood samples at	and 34 DMRs
	and targeted	n _{PTSD} = 39	years			validate and		3 months, and	associated with PTSD
	(replication					replicate		targeted	status at 3 months
	sample) DNA					selected		methylation	post-rape in the
	methylation in					significant		analyses using	discovery cohort.
	rape-exposed					findings; and		DNA extracted	Targeted analysis of
	South African					investigate the		from peripheral	methylation in BRSK2
	females with and					longitudinal		blood collected	and ADCYAP1
	without PTSD					association		at baseline, 3	performed but
						between		and 6 months.	neither baseline nor
						methylation		Cellular	longitudinal
						profiles of		heterogeneity	methylation profiles
						targeted genes		was accounted	predict PTSD
						and PTSD		for in analyses.	symptom severity
						symptomology			when covariates are
									included in models.
Pereira et al.	Longitudinal study	205 dyads of	Children: 4.64	Mothers:	African American	To examine	TSCYC	Child rs1360780	Association between
(2021)	of offspring PTSD	trauma-	± 0.84 years	100%	49%,	whether	(children)	genotype	maternal and child
	risk in 205 intimate	exposed		Children:	Hispanic/Latinx	childhood FKBP5	and PCL-C	measured in	PTSD symptoms was
	partner violence-	mothers and		51%	33%, European	genotype	(mother) at	DNA extracted	moderated by FKBP5
	exposed mother-	their			American 18%,	interacts with	baseline	from saliva or	genotype such that
	offspring dyads in	preschool			other 1%	child trauma	and 6-9	buccal cells	these symptoms
	the USA	children				exposure to	months		were only associated
						increase risk for			among children with
						PTSD and			the minor T allele
						whether this			(CT/TT), but not the
						genotype			homozygous CC
						moderates the			allele.
						relationship			
						between			
						maternal and			

						child PTSD			
Schultebrauck s et al. (2021)	Longitudinal predictive study of participants admitted to hospital emergency departments in Amsterdam (Netherlands)	n _{Total} = 417 n _{Training} = 335 n _{Testing} = 82	46.09 ± 15.88 years	37.20%	Not specified but recruitment in the Netherlands with Dutch language proficiency required	To construct ML models for PTSD symptom trajectories over 12 months using biomedical data typically available upon hospital admission	IES-R at baseline, 1, 3, 6 and 12 months and CAPS- IV at 12 months	Physiological- and endocrine- related markers of sympathetic nervous system activity, hypothalamic- pituitary-adrenal axis, and hypothalamic- pituitary-thyroid axis activity, and information pertaining to DHEA levels	The 15 most influential variables in differentiating end-point PTSD status included thyroid stimulating hormone, cortisol, DHEA and free thyroxine.
Tamman et al. (2022)	Longitudinal study of US military veterans without PTSD recruited to the NHRVS study	n = 1083	64.7 ± 12.5 years	5.3%	European 100%	To evaluate how polygenic risk scores interact with social- environmental factors to predict incident PTSD	PCL-IV at baseline and PCL-5 at 2, 4 and 7 years	Polygenic risk score determined from whole-genome genotyping of DNA extracted from saliva samples	Higher polygenic risk score predicted increased risk of screening positive for PTSD over 7 years but only in participants with insecure attachment.
Vuong et al. (2022)	Longitudinal observational study of 455 rape- exposed South African women recruited to the RICE study	n = 455	25.3 ± 5.5 years	100%	Black African 100%	To examine the association between <i>ADIPOQ</i> variants, alone and in interaction with childhood trauma, on PTSD symptom severity	DTS at baseline, 3 and 6 months	Genotyping of 8 <i>ADIPOQ</i> SNPs (rs16861194, rs16861205, rs17300539, rs2241766, rs6444174, rs822395, rs1402697 and rs1501299) using DNA extracted from whole blood	rs6444174TT genotype was associated with lower baseline PTSD symptoms in the unadjusted model. No genotype was associated with change in PTSD symptom severity over time and the genotype x childhood trauma

									interaction was not tested
Vuong et al. (2022)	Longitudinal observational study 1135 rape-exposed and unexposed South African women recruited to the RICE study	n _{Total} = 1135 n _{rape-exposed} = 542 n _{unexposed} = 593	Total: 25.2 ± 5.4 years Rape- exposed: 24.7 ± 5.3 years Unexposed: 25.7 ± 5.5 years	100%	Black African 100%	To evaluate the relationship between adiponectin levels and probable PTSD risk, and to determine whether rape exposure moderates this relationship	MINI PTSD at baseline and DTS at 0, 3 and 6 months	Adiponectin assays performed using serum collected at baseline	Participants with mid to high adiponectin levels had a reduced risk of probable PTSD at 6 months follow- up that was independent of adiposity. There was no significant interaction with rape exposure.
Wani et al. (2021)	Prospective US population-based longitudinal cohort study of participants recruited to the DNHS study	n = 148	54.57 ± 12.79	60%	African American 93.8%	To apply ML models to psychopathology , social adversity, and glucocorticoid receptor regulatory network centred DNA methylation data to predict PTSD symptom severity	PCL-C collected across 5 waves	Genome-wide DNA methylation assessed using DNA extracted from 500 blood samples collected across different waves from 190 participants. Cellular heterogeneity was accounted for in analyses.	ML models identified that prior PTS symptom severity is the strongest predictor in ML models. 44 glucocorticoid receptor regulatory network DMPs were significantly associated with prospective PTSD symptom severity.
Wuchty et al. (2021)	Longitudinal predictive study of adults admitted to emergency units in two US hospitals	RNA group n= 366 <u>Genotype</u> and RNA group n _{total} = 297 n _{PTSD} = 108	Genotype and RNA group 34.9 ± 12.7 years	43%	Black/African American 69.9%, Caucasian 24.4%, Hispanic/Latino 14%	To determine whether an integrative transcriptomic- genomic approach can highlight blood- based markers predictive of PTSD and/or major depressive	PSS-I at 6 months	Transcriptome and eQTL analysis using blood collected at baseline. Control for sample cell composition not reported.	Study identified 13 driver causal genes and 458 paths from driver to corresponding dysregulated genes in PTSD.

						disorder symptoms six months after admission to an emergency unit			
Yang et (2021)	al. Longitudinal study of US Combat veterans from the Operation Iraqi Freedom/Operatio n Enduring Freedom conflicts recruited to the PTSD Systems Biology Consortium study	Cross- sectional discovery N _{Total} = 162 n _{PTSD} = 80 Cross- sectional validation n _{Total} = 53 n _{PTSD} = 26 Longitudinal recall N _{Total} = 55	Cross- sectional discovery With PTSD: 32.7 ± 7.4 years Without PTSD: 32.5 ± 8.0 years Cross- sectional validation With PTSD: 36.9 ± 10.2 years Without PTSD: 34.0 ± 9.4 years Longitudinal recall With PTSD: 33.0 ± 7.5 years With subthreshold PTSD: 37 ± 8.2 years Without PTSD: 35.1 ± 7.5 years	0%	Across cohorts: Hispanic 36%, non-Hispanic Asian 5%, non- Hispanic Black 23%, non-Hispanic White 32%, non- Hispanic other 7%	To investigate cross-sectional and longitudinal biological aging in PTSD using an epigenetic clock estimate sensitive to age- related morbidity and mortality	SCID and CAPS-IV at baseline and three years	DNAm GrimAge epigenetic clock estimate using genome-wide DNA methylation profiles assessed in DNA extracted from blood at baseline and three years. Cellular heterogeneity was accounted for in analyses.	PTSD status was associated with advanced biological aging, and CAPS score was positively associated with epigenetic age acceleration. Longitudinal analyses found a positive correlation between change in epigenetic age and change in PTSD symptom scores.

685 The systematic review is limited to original research manuscripts published from 1 January 2022 to 31 December 2023. The primary findings column only reports the results of analyses

686 specifically assessing the relationships between PTSD symptomology and molecular measures. Participant age is reported as mean and standard deviation unless otherwise noted.

687 Abbreviations: 2-AG: 2-arachidonoylglycerol; Aβ40: amyloid β-40; Aβ42: amyloid β-42; AEA: N-arachidonoylethanalomine; STARRS: Study to Assess Risk and Resilience in Servicemembers;

688 CAPS-5: Clinician-Administered PTSD Scale for DSM5; CAPS-IV: Clinician-Administered PTSD Scale for DSM-IV; CRP: C-reactive protein; DHEA: dehydroepiandrosterone; DMP: differentially

689 methylated position; DMR: differentially methylated region; DNHS: Detroit Neighbourhood Health Study; eQTL: expression quantitative trait loci; GFAP: glial fibrillary acid protein; IES-R:

690 Impact of Event Scale – Revised; IL-1β: interleukin-1β; IL-10: interleukin-10; IL-6: interleukin-6; LASC: Los Angeles Symptoms Checklist; meQTL: methylation quantitative trait loci; MINI: Mini

691 International Neuropsychiatric Interview; ML: machine learning; MRS: Marine Resilience Study; NFL: neurofilament light chain; NHRVS = National Health and Resilience in Veterans Study;

692 NSE: neuron-specific enolase; PCL-5: PTSD Checklist for DSM5; PCL-C: PTSD Checklist civilian version; PCL-IV: PTSD Checklist for DSM-IV; pNfH: phosphorylated neurofilament heavy chain;

693 PPQ: Perinatal PTSD Questionnaire; PRISMO: Prospective Research in Stress-Related Military Operations; PTS: posttraumatic stress; PTSD: posttraumatic stress disorder; PSS-I: PTSD Symptom

694 Scale – Interview; RICE: Rape Impact Cohort Evaluation; SCID: Structured Clinical Interview for DSM; SRIP: Self-Rating Inventory for PTSD; TNFα: tumour necrosis factor α; TRACTS:

695 Translational Research Center for TBI and Stress Disorders; TSCYC: Trauma Symptom Checklist for Young Children

Table 2: Quality assessment of included studies according to the Systematic Appraisal of Quality in Observational Research tool

Study	Sample	Control/comparison group	Exposure / outcome measures	Distorting influences	Reporting of data	Overall study quality
Chen et al. (2022)	Highschool students exposed to the Wenchuan earthquake. Sampling method, representativity and appropriateness of sample size are unclear. [Quality: inadequate]	IL-10 rs1800872 genotypes. Control group is identifiable and source is clear. [Quality: adequate]	Exposure: social and environmental factors and IL-10 rs1800872 genotype. Outcome: PTSD symptom severity. Exposure and outcome measures adequately assessed. [Quality: adequate]	Demographic and environmental factors considered. [Quality: adequate]	No statement regarding missing data. Data clearly and accurately presented with results indicating whether test statistics reached different p-value thresholds. [Quality: unclear]	Moderate
Coredero et al. (2022)	Intimate partner violence- exposed women, with and without PTSD, and their offspring recruited to the Geneva Early Childhood Stress Study. Sample source, sampling method and inclusion/exclusion criteria are clear. Representativity and appropriateness of sample size are unclear. [Quality: unclear]	Women exposed to intimate partner violence without PTSD. Control group is identifiable and matched to cases, source is clear. [Quality: adequate]	Exposure: Maternal PTSD and NR3C1 methylation. Outcome: Infant NR3C1 methylation and child internalising and externalising behaviour. Exposure and outcome measures adequately assessed. [Quality: adequate]	Offspring demographic factors and maternal trauma- and stress-related variables considered. [Quality: adequate]	Missing data addressed in text. Data clearly and adequately represented with CIs and p-values. [Quality: adequate]	High
deRoon-Cassini et al. (2022)	Adults hospitalised for traumatic injury. Sample source and inclusion/exclusion criteria are clear and appropriateness of sample size is addressed. Sampling method and representativity are unclear. [Quality: unclear]	Minority status (not Caucasian, non-Hispanic), female sex, and SNP genotypes. Control group is identifiable and source is clear. Whether case-control differences controlled for is unclear. [Quality: unclear]	Exposure: genotype, 2-AG, AEA and plasma cortisol concentrations. Outcome: PTSD symptom severity. Exposure and outcome measures adequately assessed. [Quality: adequate]	Models stratified by sex and race/ethnicity. [Quality: Adequate]	Missing data addressed in text. Data clearly and adequately represented with p- values. [Quality: adequate]	Moderate
Hawn et al. (2022)	Cohort of US military veterans recruited to the TRACTS study. Inclusion/exclusion criteria are clear. Referenced paper provides	N/A	Exposure: Lifetime PTSD severity and baseline levels of inflammatory and neuropathology markers and <i>AIM2</i> methylation. Outcome	Demographic and cell type measures considered. [Quality: adequate]	Missing data addressed in text. Data clearly and adequately	High

	detail on participant source and sampling method. Representativity and appropriateness of sample size are unclear. [Quality: unclear]		measures: Follow-up inflammatory and neuropathology marker levels. Exposure and outcome measures adequately assessed. [Quality: adequate]		represented with p- values. [Quality: adequate]	
Katrinli et al. (2022)	Military personnel/veterans recruited to three cohort studies: MRS (USA), Army STARRS (USA) and PRISMO (Netherlands). Sample source, sampling method and representativity are clear. Cohort-specific inclusion/exclusion criteria and adequateness of sample size unclear. [Quality: unclear]	Trauma-exposed controls falling below study-specific PTSD severity score thresholds. Control group is identifiable, source is clear and case-control differences checked for. [Quality: adequate]	Exposure: Deployment and epigenome-wide DNA methylation. Outcome: PTSD symptom severity. Exposure and outcome measures adequately assessed. [Quality: adequate]	Demographic and methylation assessment-related variables considered. [Quality: adequate]	Missing data addressed in text. Data clearly and adequately represented with p- values. [Quality: adequate]	High
Landoni et al. (2022)	Pregnant women attending birth preparation courses. Source, sampling method and inclusion/exclusion criteria are clear. Representativity and adequateness of sample size are unclear. [Quality: unclear]	<i>5-HTTPLPR</i> polymorphisms. Control group is identifiable and source is clear. [Quality: adequate]	Exposure: 5-HTTPLPR polymorphisms. Outcome: PTSD symptom severity. Exposure and outcome measures adequately assessed. [Quality: adequate]	Whether covariates or confounding variables were considered is unclear. [Quality: inadequate]	Missing data addressed in text. Data clearly and accurately represented with results indicating whether test statistics reached different p-value thresholds. [Quality: adequate]	Moderate
Lori et al. (2021)	Adult participants admitted to a hospital emergency unit. Source, sampling method and inclusion/exclusion criteria are clear. Representativity and appropriateness of sample size are unclear. [Quality: unclear]	N/A	Exposure: Transcriptome, eQTL and meQTL. Outcome: PTSD symptom trajectories. Exposure and outcome measures adequately assessed. [Quality: adequate]	Demographic and trauma- and methylation assessment-related variables considered. [Quality: adequate]	Missing data addressed in text but final sample size not explicitly stated for all individual analyses. Data are clearly and accurately represented with p- values provided. [Quality: unclear]	Moderate

Mehta et al. (2022)	Trauma-exposed paramedicine students. Source and sampling method are clear. Inclusion/exclusion criteria, representativity and adequateness of sample size are unclear. [Quality: inadequate]	N/A	Exposure: psychological distress, PTSD symptom severity, professional quality of life, sense of organisational membership and social support. Outcome: Change in epigenetic age estimation. Exposure and outcome measures adequately assessed. [Quality: adequate]	Demographic, clinical and methylation assessment-related factors considered. [Quality: Adequate]	Missing data addressed in text. Data are clearly and accurately presented with p-values provided. [Quality: adequate]	Moderate
Morris et al. (2022)	Young women with experience of interpersonal violence. Source, sampling method and inclusion/exclusion criteria are clear. Representativity and appropriateness of sample size are unclear. [Quality: unclear]	N/A	Exposure: Biopsychosocial factors including sociodemographic, cognitive, clinical and trauma- related data. Outcome: PTSD status. Exposure and outcome measures adequately assessed. [Quality: adequate]	Range of factors are included in ML model and methods were employed to address model overfitting. [Quality: adequate]	Missing features imputed. Results are clearly and accurately represented with p- values provided. [Quality: adequate]	High
Nöthling et al. (2021)	Rape-exposed women recruited to the RICE study. Source and inclusion/exclusion criteria are clear and referenced paper provides detail on sampling method. Representativity and appropriateness of sample size are unclear. [Quality: unclear]	Participants falling below study-specific PTSD severity score thresholds. Control group is identifiable and matched to cases, source is clear. [Quality: adequate]	Exposure: Epigenome-wide and targeted DNA methylation. Outcome: PTSD status and symptom severity. Exposure and outcome measures adequately assessed. [Quality: adequate]	Demographic and trauma- and methylation assessment-related variables considered. [Quality: adequate]	Missing data imputed. Results are clearly and accurately represented with p- values provided. [Quality: adequate]	High
Pereira et al. (2021)	Trauma-exposed mothers recruited to the MAPS study and their children. Source, sampling approach and inclusion/exclusion criteria are clear. Representativity and appropriateness of sample size are unclear. [Quality: unclear]	rs1360780 genotype. Control group is identifiable and source is clear. [Quality: adequate]	Exposure: child <i>FKBP5</i> genotype and maternal PTSD symptom severity. Outcomes: Child PTSD symptom severity. Exposure and outcome measures adequately assessed. [Quality: adequate]	Demographic and trauma-related variables considered. [Quality: adequate]	No statement regarding missing data. Data are clearly and accurately represented with p- values provided. [Quality: unclear]	Moderate
Schultebraucks et al. (2021)	Adults admitted to hospital emergency departments. Source, sampling method and inclusion/exclusion criteria are	N/A	Exposure: 51 variables including demographic, endocrine, psychophysiological, pharmacotherapeutic, PTSD	Range of factors were included in the ML model and appropriate methods	Missing features imputed. Results are clearly and accurately	Moderate

	clear. Representativity and appropriateness of sample size are unclear. [Quality: unclear]		symptom severity and trauma- and injury-related data. Outcome: PTSD symptom trajectories status. Exposure and outcome measures adequately assessed. [Quality: adequate]	were employed to refine parameter selection and address model overfitting. [Quality: adequate]	represented with p- values provided. [Quality: adequate]	
Tamman et al. (2022)	Military veterans without PTSD. Source, sampling procedure and representativity are clear. Referenced paper provides detail on inclusion/exclusion criteria. Adequateness of sample size unclear. [Quality = adequate]	Participants without an incident positive screen for PTSD. Control group is identifiable, source is clear and case-control differences checked for. [Quality: adequate]	Exposures: polygenic risk score, attachment style and social network size. Outcome: PTSD status. Exposure and outcome measures adequately assessed. [Quality: adequate]	Demographic, clinical, and trauma-related variables considered. [Quality: adequate]	Missing data imputed. Results are clearly and accurately reported with CIs and p-values provided. [Quality: adequate]	High
Vuong et al. (2022)	Rape-exposed women recruited to the RICE study. Source and inclusion/exclusion criteria are clear and referenced paper provides detail on sampling method. Representativity and appropriateness of sample size are unclear. [Quality: unclear]	Genotype of eight <i>ADIPOQ</i> variants. Control group is identifiable and source is clear. [Quality: adequate]	Exposure: Eight ADIPOQ SNPs. Outcome: PTSD symptom severity. Exposure and outcome measures adequately assessed. [Quality: adequate]	Demographic and trauma-related variables considered. [Quality: adequate]	Missing data imputed. Results are clearly and accurately reported with p-values provided. [Quality: adequate]	High
Vuong et al. (2022)	Women with and without rape exposure recruited to the RICE study. Source and inclusion/exclusion criteria are clear and referenced paper provides detail on sampling method. Representativity and appropriateness of sample size are unclear. [Quality: unclear]	Low adiponectin tertile. Control group is identifiable, source is clear and case- control differences checked for. [Quality: adequate]	Exposure: Rape exposure and adiponectin levels. Outcome: Probable PTSD. Exposure and outcome measures adequately assessed. [Quality: adequate]	Demographic, clinical and trauma-related variables considered. [Quality: adequate]	Missing data imputed. Results are clearly and accurately reported with p-values provided. [Quality: adequate]	High
Wani et al. (2021)	Adult participants recruited to the DNHS. Adequateness of sample size is clear. Referenced paper provides detail on participant source and sampling method. Representativity and inclusion/exclusion criteria are not clear. [Quality: unclear]	N/A	Exposure: Psychological, social adversity and DNA methylation profiles. Outcome: PTSD symptom severity. Exposure and outcome measures adequately assessed. [Quality: adequate]	Cell type considered. Feature selection process adjusted to account for hidden confounders within ML models. [Quality: adequate]	Missing data imputed. Results are clearly and accurately represented. [Quality: adequate]	High

Wuchty et al. (2021)	Adults admitted to hospital emergency departments. Source, sampling method and inclusion/exclusion criteria are clear. Representativity and appropriateness of sample size are unclear. [Quality: uncertain]	Trauma-exposed controls. Control group is identifiable and source is clear. Whether case-control differences controlled for is unclear. [Quality: adequate]	Exposure: Transcriptomic and genomic profiles. Outcome: PTSD status. Exposure and outcome measures adequately assessed. [Quality: adequate]	Statistical approaches to identify and adjust for hidden sources of variation associated with traditional demographic variables used. [Quality: adequate]	Missing data addressed in text. Results clearly and accurately reported. [Quality: adequate]	High
Yang et al. (2021)	Military veterans recruited to cohorts included in the PTSD Systems Biology Consortium. Source and inclusion/exclusion criteria are clear and adequateness of sample size is addressed. Referenced paper provides detail on sampling method. Representativity is unclear. [Quality: adequate]	Military veterans without PTSD. Control group is identifiable, source is clear and case-control differences were checked for. [Quality: adequate]	Exposure: PTSD status and change in symptom severity. Outcome: GrimAge acceleration. Exposure and outcome measures adequately assessed. [Quality: adequate]	Demographic, clinical and immunological variables considered. [Quality: adequate]	No statement regarding missing data. Data is clearly and accurately reported with p- values provided. [Quality: unclear]	High

698 Abbreviations: 2-AG: 2-arachidonoylglycerol; AEA: N-arachidonoylethanalomine; CIs: confidence intervals; DNHS: Detroit Neighbourhood Health Study; eQTL: expression quantitative trait loci;

699 IL-10: interleukin-10; MAPS: Multidimensional Assessment of Preschoolers; meQTL: methylation quantitative trait loci; ML: machine learning; MRS: Marine Resilience Study; PRISMO:

700 Prospective Research in Stress-Related Military Operations; PTSD: posttraumatic stress disorder; RICE: Rape Impact Cohort Evaluation; SNP: single nucleotide polymorphism; STARRS: Study to

701 Assess Risk and Resilience in Servicemembers; TRACTS: Translational Research Center for TBI and Stress Disorders

702 Figure captions

- 703 Graphical abstract. Recent longitudinal studies implicate inflammatory, stress response, and learning
- and memory processes in the relative risk of developing posttraumatic stress disorder. However,
- further research is required before the clinical value of these biological correlates can be realised.
- This research should have greater representation from low- and middle-income countries in order to
- 707 better reflect the global trauma burden.



710 Figure 1. Study selection flow diagram. Molecular biology and PTSD



711

- 713 Figure 2: Annual count of number of publications retrieved from PubMed using the systematic
- review search string. The results are based on the following query: (("post-traumatic stress" [All
- 715 Fields]) OR ("posttraumatic stress" [All Fields]) OR (PTSD [All Fields])) AND ((neurobiolog* [All Fields])
- 716 OR (genom* [All Fields]) OR (DNA [All Fields]) OR ("stress hormone" [All Fields])) AND
- 717 (English[Language]) NOT (animal). The search was limited to studies published up to 31 December
- 718 2022.

